MARLBOROUGH, Mass.,
Sept. 30, 2015 /PRNewswire/
-- Hologic, Inc. (Nasdaq: HOLX) announced today that
award-winning actress and singer Kristin
Chenoweth will join Steve
MacMillan, the Company's Chairman, President and Chief
Executive Officer, to ring the Nasdaq Opening Bell on October 1, the first day of Breast Cancer
Awareness Month.
This is the 10th year in a row that Nasdaq has invited Hologic
to preside over its Opening Bell ceremony to kick off Breast Cancer
Awareness Month.
"Hologic's Genius™ 3D Mammography™
exams are the market leader for breast cancer screening," MacMillan
said. "Genius™ 3D exams allow doctors to see
cancers and precancerous cells more clearly than conventional
mammography. They detect significantly more invasive breast
cancers, while simultaneously reducing false positives."
Clinical studies have shown that Genius™ 3D Mammography™
exams are more accurate than traditional 2D mammograms alone.
The Genius™ exam is the only mammogram proven to
reduce callbacks by up to 40 percent, and detect 41 percent more
invasive cancers than 2D screenings.1,2
During Breast Cancer Awareness Month, Chenoweth will serve as
spokeswoman for a national campaign to encourage insurance
companies to cover Genius™ 3D Mammography™ exams.
Chenoweth, who is touring the country in support of her latest
album, Coming Home, is the daughter of a two-time breast
cancer survivor and understands how important it is that women have
access to the best screening options available.
"Even though one in eight women will develop breast
cancer3, not all insurance carriers cover the more
accurate 3D screening procedure that's available to fight against
the disease," Chenoweth said. "That's why I'm partnering with
Hologic and urging women across the country to speak up. If
breast cancer is found early, the five-year survival rate is almost
100 percent4 – that's a great reason to seek out this
technology and encourage your insurance carrier to fully cover the
exam."
As part of the campaign, Chenoweth will conduct interviews
throughout October with national and regional media outlets.
In addition, a social media campaign will include the support
of additional high-profile celebrities.
The Genius™ 3D Mammography™ exam is FDA-approved and
available on the Hologic Selenia® Dimensions®
system. Since 2011, over 8 million women in the U.S. have
benefited from the exam. Additional information, as well as a
locator to find imaging sites offering Genius™ 3D
Mammography™ exams, can be found at
http://mygenius3d.com/.
Webcast Information
Hologic's participation in the Nasdaq Opening Bell ceremony will
be aired live at https://new.livestream.com/NASDAQ/live and with
closed captioning on the Nasdaq MarketSite tower in Times
Square. A video of the Opening Bell ceremony will be archived
for one year on the Nasdaq site.
About Hologic
Hologic, Inc. is a leading developer, manufacturer and supplier
of premium diagnostic products, medical imaging systems and
surgical products. The Company's core business units focus on
diagnostics, breast health, GYN surgical, and skeletal
health. With a unified suite of technologies and a robust
research and development program, Hologic is dedicated to The
Science of Sure. For more information, visit www.hologic.com.
Forward-Looking Statements
This news release may contain forward-looking information that
involves risks and uncertainties, including statements about the
use of Hologic's Genius™ 3D Mammography™
exams. There can be no assurance that the exams will achieve
the benefits described here, or that such benefits will be
replicated in any manner with respect to an individual
patient. The actual effect of the use of the exam can only be
determined on a case-by-case basis depending on the particular
circumstances and patient in question. In addition, there can
be no assurance that insurance coverage of Genius™ 3D
Mammography™ exams will increase, or that Hologic will
achieve its sales goals for the product. Hologic expressly
disclaims any obligation or undertaking to release publicly any
updates or revisions to the statements presented here to reflect
any change in the Company's expectations or any change in events,
conditions or circumstances on which any such statements are
based.
Contacts
|
|
|
|
Media
|
Investors
|
Jim
Culley
|
Michael
Watts
|
Senior Director,
Corporate Communications
|
Vice President,
Investor Relations and
|
(781)
999-7583
|
Corporate
Communications
|
|
(858)
410-8588
|
1. Friedewald S, Rafferty E, Rose S, et al. Breast cancer
screening using tomosynthesis in combination with digital
mammography. JAMA. 2014;311(24):2499-2507.
2. Rose S, Tidwell A, Bujnock L, et al. "Implementation of
Breast Tomosynthesis in a Routine Screening Practice: An
Observational Study." American Journal of Roentengenology. 2013
Jun; 200(6): 1401-1408.
3. Breastcancer.org. US breast cancer statistics.
Breastcancer.org.
http://www.breastcancer.org/symptoms/understand_bc/statistics.
Accessed on: September 29, 2015.
4. National Breast Cancer Foundation, Inc. Stages 0 & 1:
what does this mean to have stage 1 breast cancer? National Breast
Cancer Foundation, Inc.
http://www.nationalbreastcancer.org/breast-cancer-stage-0-and-stage-1.
Accessed on: September 29, 2015.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/hologic-ceo-steve-macmillan-and-award-winning-actress-and-singer-kristin-chenoweth-to-kick-off-breast-cancer-awareness-month-by-ringing-the-nasdaq-opening-bell-on-october-1-300151396.html
SOURCE Hologic, Inc.